Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Increase in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,038,967 shares, an increase of 1,004.7% from the April 15th total of 275,084 shares. Based on an average daily trading volume, of 17,378,163 shares, the short-interest ratio is currently 0.2 days. Currently, 29.1% of the company’s stock are short sold.

Institutional Trading of Calidi Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Calidi Biotherapeutics in the 4th quarter valued at $25,000. Warberg Asset Management LLC purchased a new stake in Calidi Biotherapeutics in the 3rd quarter valued at $28,000. Geode Capital Management LLC raised its position in Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC purchased a new stake in Calidi Biotherapeutics in the 4th quarter valued at $173,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Price Performance

Shares of CLDI opened at $0.20 on Tuesday. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.21. Calidi Biotherapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $19.20. The company has a market cap of $2.16 million, a P/E ratio of -0.03 and a beta of 1.38. The firm’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.90.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last issued its earnings results on Friday, March 27th. The company reported $0.45 earnings per share (EPS) for the quarter.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.